“Semaglutide is very effective for weight loss,” says Dr. Saunders. In fact, a 2021 phase 3 clinical trial found that 2.4 ...

Eli Lilly's orforglipron could have a few advantages over a pill from Novo Nordisk, including a lack of dietary restrictions ...

The FDA has granted accelerated approval of Wegovy® (semaglutide) for adults with moderate to advanced metabolic ...

The latest results from a trial of a pill form popular GLP-1 medications offer enough information for the Eli Lilly to ...

The results of the ATTAIN-2 study, which involved people with obesity or overweight and type 2 diabetes, showed that the oral ...

With around 73 percent of Americans enjoying their daily coffee fix, it’s natural to wonder how your morning cup might ...

An estimated 2·1 billion adults worldwide are affected by overweight and obesity, a figure projected to reach 3·8 billion by ...

Wegovy is now approved by the FDA to treat metabolic-associated steatohepatitis in adults with moderate-to-advanced fibrosis ...

Eli Lilly and Company LLY is a key player in the diabetes and obesity drug market, mainly due to the significant popularity ...

The FDA has granted accelerated approval to semaglutide (Wegovy; Novo Nordisk) injection 2.4 mg for the treatment of adults with metabolic dysfunction–associated steatohepatitis (MASH) with moderate ...

GLP-1 receptor agonist medications like Ozempic have been talked about so much that its side effects (like nausea and ...

Definitive conclusions regarding the association between semaglutide and nonarteritic anterior ischemic optic neuropathy ...